AI assistant
Neuland Laboratories Limited. Interim / Quarterly Report 2021
62255_rns_2021-05-12_8d9bcd69-4770-4e46-9ba0-27ca87b2cc64.pdf
Interim / Quarterly Report
Open in viewerOpens in your device viewer
May 12, 2021
To BSE Limited Phiroze Jeejeebhoy Towers, 25th Floor, Dalal Street, Mumbai – 400 001
To The National Stock Exchange of India Ltd Exchange Plaza, Bandra Kurla Complex, Bandra (E) Mumbai – 400 001
Scrip Code: 524558
Scrip Code: NEULANDLAB; Series: EQ
Dear Sirs,
Sub: Compliance with Regulation 47(1)(b) of the SEBI Listing Regulations, 2015
Please find attached herewith copies of the newspaper publication of Audited Financial Results for the quarter and year ended March 31, 2021, published in Financial Express and Andhra Prabha on May 12, 2021 for your reference.
This is for your information and records.
Yours faithfully,
For Neuland Laboratories Limited
Sarada Bhamidipati Digitally signed by Sarada Bhamidipati DN: cn=Sarada Bhamidipati, o=Neuland Laboratories Limited, ou, email=[email protected], c=IN Date: 2021.05.12 14:10:22 +05'30'
Sarada Bhamidipati Company Secretary
Encl: As above
FINANCIAL EXPRESS WEDNESDAY, MAY 12, 2021
| Regd. office: Sanali Info park, 'A' Block, Ground floor8-2-120/113, Road No.2, Banjara Hills, Hyderabad-500034EXTRACT OF CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2021 | (Amount in lakhs of x, unless otherwise stated) | NEULAND | ||
|---|---|---|---|---|
| SLParticularsNo. | Quarter Ended31.03.2021 | Quarter Ended31.03.2020 | Year Ended31.03.2021 | Year Ended31.03.2020 |
| Revenue from operations1Net profit for the period before tax$\overline{\mathbf{z}}$Net profit for the period after tax3Total comprehensive income for the period4Paid-up Equity Share Capital (Face value - ₹10 each)5Other equity (excluding revaluation reserves) as6shown in the audited balance sheetEarnings Per Share (of z10 each) (In absolute z terms)(a) Basic(b) DilutedNote 1: The financial results for the quarter and year ended 31 March 2021 have been reviewed by the Audit Committee andapproved by the Board of Directors at their meeting held on 11 May 2021.Note 2: Key Standalone Financial Information: | 24,470.472,439.011,729.261,580.931.290.0577.271.8313.4813.48 | 19, 164, 191,719.80(929.57)(894.50)1.290.0569,621.83(7.25)(7.25) | 93.691.3110,533.358.063.077,906.601.290.0577,271.83As at 31.03.2021 As at 31.03.2020 As at 31.03.2021 As at 31.03.202062.8562.85 | 76,271.085,292.251,621.051,577.651.290.0569,621.8312.6312.63 |
| Particulars | Quarter Ended31.03.2021 | Quarter Ended31.03.2020 | Year Ended31.03.2021 | Year Ended31.03.2020 |
| Revenue from operationsNet profit for the period before taxNet profit for the period after tax | 24,470.472,431.591,722.80 | 19, 186.591,707.68(935.00) | 93.691.3110.496.218.029.49 | 76,271.085.249.581,588.01 |
| Note 3: The above is an extract of the detailed format of Unaudited Financial Results filed with the Stock Exchanges underRegulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of theUnaudited Financial Results are available on the Stock Exchange websites, www.nseindia.com and www.bseindia.comand on the Company's website www.neulandlabs.comPlace: Hyderabad$$ $$ $$ $$ $$ $$ $$ $$ | For Neuland Laboratories Limited | By Order of the BoardDr. D.R.RaoExecutive ChairmanCHINA COACTESTS |
WEDNESDAY, MAY 12, 2021
| NEULAND LABORATORIES LIMITED(CIN: L85195TG1984PLC004393)Regd, office: Sanali Info park, 'A' Block, Ground floor8-2-120/113, Road No.2, Banjara Hills, Hyderabad-500034EXTRACT OF CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2021 | NEULAND | ||||
|---|---|---|---|---|---|
| SI.No. | Particulars | Quarter Ended31.03.2021 | Quarter Ended31.03.2020 | (Amount in lakhs of x, unless otherwise stated)Year Ended31.03.2021 | Year Ended31.03.2020 |
| ٠23456$\overline{7}$ | Revenue from operationsNet profit for the period before taxNet profit for the period after taxTotal comprehensive income for the periodPaid-up Equity Share Capital (Face value - ₹10 each)Other equity (excluding revaluation reserves) asshown in the audited balance sheetEarnings Per Share (of <10 each) (In absolute < terms)(a) Basic(b) Diluted | 24.470.472.439.011,729.261,580.931,290.0577.271.8313.4813.48 | 19, 164, 191,719.80(929.57)(894.50)1.290.0569.621.83As at 31,03,2021 As at 31,03,2020 As at 31,03,2021 As at 31,03,2020(7.25)(7.25) | 93.691.3110.533.358.063.077,906.601.290.0577, 271, 8362.8562.85 | 76,271.085.292.251,621.051,577.651,290.0569,621.8312.6312.63 |
| Note 1: The financial results for the quarter and year ended 31 March 2021 have been reviewed by the Audit Committee andapproved by the Board of Directors at their meeting held on 11 May 2021.Note 2: Key Standalone Financial Information: | |||||
| Particulars | Quarter Ended31.03.2021 | Quarter Ended31.03.2020 | Year Ended31.03.2021 | Year Ended31.03.2020 | |
| Revenue from operationsNet profit for the period before taxNet profit for the period after tax | 24,470.472.431.591,722.80 | 19, 186.591,707.68(935.00) | 93,691.3110,496.218.029.49 | 76,271.085.249.581.588.01 | |
| Note 3: The above is an extract of the detailed format of Unaudited Financial Results filed with the Stock Exchanges underRegulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of theUnaudited Financial Results are available on the Stock Exchange websites, www.nseindia.com and www.bseindia.comand on the Company's website www.neulandlabs.comPlace: HyderabadDate: 11 May 2021 | By Order of the BoardFor Neuland Laboratories LimitedDr. D.R.RaoExecutive Chairman(DIN 00107737) |